Stockscreener 앱 받기
27.95
5.52%
-1.5822
전일 마감가:
$29.53
열려 있는:
$28.73
하루 거래량:
1.38M
Relative Volume:
0.67
시가총액:
$2.88B
수익:
$139.74M
순이익/손실:
$-79.99M
주가수익비율:
-27.52
EPS:
-1.0157
순현금흐름:
$-360.05M
1주 성능:
-13.68%
1개월 성능:
-9.06%
6개월 성능:
+28.45%
1년 성능:
+61.74%
1일 변동 폭
$27.73
$29.34
1주일 범위
$27.73
$34.38
52주 변동 폭
$15.35
$36.44
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.99 | 3.28B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
436.48 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.88 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.67 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.44 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.46 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
BEAM's Q1 loss wider than expected, revenues beat estimates - MSN
Beam Therapeutics Stock Stumbles After Post-Rally Shakeout - TipRanks
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
BEAM Maintained by Bernstein -- Price Target Lowered to $39.00 - GuruFocus
AlphaDetect Partners with Beam Therapeutics to Enhance Detection Efforts - Intellectia AI
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 - ChartMill
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story - Seeking Alpha
Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference - Yahoo Finance
Beam Therapeutics to present sickle cell therapy data at EHA - Investing.com
Beam Therapeutics to Present Positive Biomarker Data from BEACON Trial of Ristoglogene Autogetemcel for Sickle Cell Disease at EHA2026 - Quiver Quantitative
Beam Therapeutics to present sickle cell therapy data at EHA By Investing.com - Investing.com India
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 - The Manila Times
(BEAM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Analysts Are Upgrading Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results - Moomoo
Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Evercore Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $45 - Moomoo
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates - The Globe and Mail
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
MSN Money - MSN
JonesTrading Initiates Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $35 - Moomoo
Beam Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Beam Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q1 Revenue $31.7M, vs. FactSet Est of $11.0M - marketscreener.com
Beam Therapeutics (NASDAQ: BEAM) boosts Q1 2026 collaboration revenue, secures new credit facility - Stock Titan
Beam Therapeutics Q1 net loss narrows beating analyst estimates - TradingView
Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q1 Revenue $31.7M, Vs. FactSet Est of $11.0M - Moomoo
Beam Therapeutics (BEAM) boosts Q1 revenue and advances late-stage gene-editing pipeline - Stock Titan
Beam targets sickle cell filing as AATD drug heads to pivotal study - Stock Titan
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates - marketscreener.com
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure - Yahoo Finance
Prime Editing and CRISPR Market is expected to Hit US$ 11.46 - openPR.com
Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus - Yahoo Finance
Beam Therapeutics Advances Base Editing Platform with Strong Clinical Data - HarianBasis.co
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now? - Insider Monkey
14 Stocks on Jim Cramer’s Radar: Nokia, Cameco, and AI Stocks’ Dip - Insider Monkey
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation” - Insider Monkey
Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily
Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake - Stock Titan
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Insider Monkey
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM - MarketBeat
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Beam Therapeutics (BEAM) Projected to Post Earnings on Tuesday - MarketBeat
Beam Therapeutics shows rising relative strength; still shy of key benchmark - MSN
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '26 |
Sale |
24.58 |
30,078 |
739,317 |
1,047,205 |
| Simon Amy | Chief Medical Officer |
Apr 01 '26 |
Sale |
24.58 |
6,700 |
164,686 |
102,735 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '26 |
Sale |
24.58 |
3,242 |
79,688 |
51,171 |
| Bellon Christine | Chief Legal Officer |
Apr 01 '26 |
Sale |
24.58 |
5,956 |
146,398 |
109,711 |
| Ciaramella Giuseppe | President |
Apr 01 '26 |
Sale |
24.58 |
11,810 |
290,290 |
218,406 |
| Evans John M. | CEO |
Mar 30 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Sale |
22.76 |
25,000 |
569,085 |
986,667 |
| Evans John M. | CEO |
Mar 30 '26 |
Sale |
22.37 |
25,000 |
559,230 |
986,667 |
0.44%
자본화:
|
볼륨(24시간):